Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139937 | 0.96 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTALOX5ALDH1A1CYP3A4 | |
| SCHEMBL18285352 | 0.89 | HTT (0.50) | SMN1; SMN2HTTALOX5ALDH1A1MEN1 | |
| SCHEMBL15874264 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2HTTALOX5ALDH1A1MEN1 | |
| SCHEMBL3071640 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTALOX5ALDH1A1CYP3A4 | |
| SCHEMBL28009625 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTALOX5ALDH1A1CYP3A4 | |
| SCHEMBL5505631 | 0.83 | KMT2A (0.63) | SMN1; SMN2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3072808 | 0.82 | SMN1; SMN2 (0.80) | SMN1; SMN2HTTALOX5ALDH1A1CYP3A4 | |
| SCHEMBL1857541 | 0.82 | MAPK1 (0.56) | HTTALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL9120212 | 0.82 | MEN1 (0.47) | SMN1; SMN2HTTALOX5ALDH1A1CYP3A4 | |
| SCHEMBL18285326 | 0.82 | MEN1 (0.46) | SMN1; SMN2HTTALOX5ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004060286-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | RENOVIS, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1079820-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999059569-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | claimed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | claimed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | claimed |
| EP-1592738-B1 | RESIN COMPOSITIONS | CIBA HOLDING INC (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-7790793-B2 | Amide nucleating agent compositions | CIBA SPECIALTY CHEM. CORP. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070149663-A1 | Resin compositions | CIBA SPECIALTY CHEMICALS CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | SMN1; SMN2 8/4885HTT 13/4885ALOX5 1293/4885 |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | SMN1; SMN2 123/4885HTT 2226/4885ALOX5 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.